Abstract
BackgroundAutosomal dominant polycystic disease (ADPKD) often results in renal failure. Recently, allelic influences of PKD1 mutation types on renal survival were extensively investigated. Here, we analyzed integrated influences of PKD1 mutation types and positions on renal survival.MethodsWe included 338 (82 pedigrees) and 72 (12 pedigrees) patients with PKD1 and PKD2 mutations, respectively, identified through comprehensive gene analysis of 101 probands with ADPKD. Genetic testing was performed using next-generation sequencing, long-range PCR, and multiplex ligation-dependent probe amplification. Pathogenic mutations were identified by a software package-integrated seven databases and provided access to five cloud-based computing systems.ResultsMean renal survivals of carriers with PKD1 non-truncating-type mutations at positions upstream of G-protein-coupled receptor proteolytic site (GPS-upstream domain), transmembrane domain, or cytoplasmic C-terminal tail (CTT) domain were 70.2, 67.0, and 50.1 years, respectively (P < 0.0001); renal survival was shorter for mutation positions closer to CTT domain, suggesting its crucial role in renal prognosis. Furthermore, in truncating-type mutations, strong inactivation is anticipated on nucleotides downstream from the mutation site, implying CTT domain inactivation irrespective of mutation site. Shorter mean renal survival was found for PKD1 truncating-type than non-truncating-type mutation carriers (P = 0.0348); mean renal survival was not different between PKD1 3′- and 5′-region truncating-type mutation carriers (P = 0.4375), but was shorter in PKD1 3′-region than in 5′-region non-truncating-type mutation carriers (P = 0.0014). Variable strength of CTT domain inactivation might account for these results.ConclusionsAforementioned findings indicate that CTT domain’s crucial role in renal prognosis needs further investigation by larger studies (ClinicalTrials.gov; NCT02322385).
Highlights
ParticipantsAutosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease that leads to end-stage renal disease (ESRD) by the age of 60–70 years in approximately 50% of patients [1,2,3,4]
Mean renal survivals of carriers with PKD1 nontruncating-type mutations at positions upstream of G-protein-coupled receptor proteolytic site (GPS-upstream domain), transmembrane domain, or cytoplasmic C-terminal tail (CTT) domain were 70.2, 67.0, and 50.1 years, respectively (P \ 0.0001); renal survival was shorter for mutation positions closer to CTT domain, suggesting its crucial role in renal prognosis
In truncatingtype mutations, strong inactivation is anticipated on nucleotides downstream from the mutation site, implying CTT domain inactivation irrespective of mutation site
Summary
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease that leads to end-stage renal disease (ESRD) by the age of 60–70 years in approximately 50% of patients [1,2,3,4]. 85 and 15% of patients develop ADPKD due to PKD1 and PKD2 mutations, respectively [5,6,7,8,9,10]. Accumulating evidence indicates that these genes represent the most powerful determinant of disease severity in patients with ADPKD; survival to ESRD is 15–20 years less in patients with PKD1, than in those with PKD2 mutations [8, 11]. We analyzed integrated influences of PKD1 mutation types and positions on renal survival. Pathogenic mutations were identified by a software package-integrated seven databases and provided access to five cloud-based computing systems
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.